NASDAQ:ABIO ARCA biopharma Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ARCA biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.48 -0.01 (-0.40%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$2.40▼$2.4950-Day Range$2.24▼$2.5352-Week Range$1.71▼$3.84Volume43,706 shsAverage Volume45,770 shsMarket Capitalization$35.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ARCA biopharma MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$1.09 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.66 out of 5 starsMedical Sector1184th out of 1,412 stocksDiagnostic Substances Industry19th out of 27 stocks 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for ARCA biopharma. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.00% of the float of ARCA biopharma has been sold short.Short Interest Ratio / Days to CoverARCA biopharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ARCA biopharma has recently decreased by 14.85%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldARCA biopharma does not currently pay a dividend.Dividend GrowthARCA biopharma does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABIO. Previous Next 1.8 News and Social Media Coverage News SentimentARCA biopharma has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ARCA biopharma this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ARCA biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,092,974.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.48% of the stock of ARCA biopharma is held by insiders.Percentage Held by InstitutionsOnly 28.12% of the stock of ARCA biopharma is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of ARCA biopharma is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ARCA biopharma is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioARCA biopharma has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ABIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address About ARCA biopharma (NASDAQ:ABIO) StockARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.Read More ABIO Stock News HeadlinesJune 26, 2022 | americanbankingnews.comARCA biopharma (NASDAQ:ABIO) Now Covered by StockNews.comJune 21, 2022 | benzinga.comJacob Ma-Weaver Joins ARCA biopharma Board of DirectorsJune 19, 2022 | americanbankingnews.comARCA biopharma (NASDAQ:ABIO) Coverage Initiated by Analysts at StockNews.comJune 16, 2022 | americanbankingnews.comARCA biopharma, Inc. (NASDAQ:ABIO) Sees Significant Decrease in Short InterestMay 5, 2022 | finance.yahoo.comARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options ReviewMay 4, 2022 | seekingalpha.comARCA biopharma GAAP EPS of -$0.23May 3, 2022 | seekingalpha.comARCA biopharma: Activist's Pressure Could Make This Into A Liquidation PlayMay 2, 2022 | finance.yahoo.comARCA biopharma Announces First Quarter 2022 Financial ResultsApril 27, 2022 | msn.comARCA driver charged with felony battery after allegedly punching classmate in groinApril 18, 2022 | seekingalpha.comARCA biopharma establishes special board committee to evaluate strategic optionsApril 18, 2022 | finance.yahoo.comARCA biopharma Establishes Special Committee of the Board of DirectorsApril 5, 2022 | finance.yahoo.comAlbioma : Governance changesApril 1, 2022 | msn.comARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 StudyMarch 31, 2022 | seekingalpha.comArca biopharma fails to meet key goal in mid-stage trial for COVID-19 therapyMarch 31, 2022 | finance.yahoo.comARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical TrialMarch 14, 2022 | finance.yahoo.comARCA biopharma Announces 2021 Financial Results and Provides Corporate UpdateMarch 12, 2022 | foxnews.comTaylor Gray's NASCAR/ARCA Phoenix win salutes teammate who died in accident this weekMarch 10, 2022 | msn.comGoFundMe Created For ARCA Hauler Driver's Funeral ExpensesMarch 9, 2022 | msn.comHauler driver for ARCA team killed in crash in TexasMarch 9, 2022 | msn.comARCA hauler driver killed in accident on highwayMarch 8, 2022 | msn.comHauler driver for David Gilliland Racing's ARCA team killed in highway crashFebruary 25, 2022 | msn.comNASCAR Snapshot: Rajah Caruth races in ARCA Menards seriesFebruary 8, 2022 | finance.yahoo.comWe're Keeping An Eye On ARCA biopharma's (NASDAQ:ABIO) Cash Burn RateFebruary 2, 2022 | nasdaq.comARCA biopharma, Inc. Common Stock (ABIO)January 4, 2022 | finance.yahoo.comData on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABIO CUSIPN/A CIK907654 Webarcabio.com Phone(720) 940-2200Fax720-208-9261Employees17Year FoundedN/ACompany Calendar Last Earnings5/02/2022Today7/03/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)($1.300010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19.32 million Net MarginsN/A Pretax MarginN/A Return on Equity-34.12% Return on Assets-31.96% Debt Debt-to-Equity RatioN/A Current Ratio18.59 Quick Ratio18.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.54 per share Price / Book0.70Miscellaneous Outstanding Shares14,410,000Free Float14,341,000Market Cap$35.74 million OptionableNot Optionable Beta2.03 ARCA biopharma Frequently Asked Questions How has ARCA biopharma's stock price performed in 2022? ARCA biopharma's stock was trading at $2.15 at the beginning of the year. Since then, ABIO shares have increased by 15.3% and is now trading at $2.48. View the best growth stocks for 2022 here. When is ARCA biopharma's next earnings date? ARCA biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for ARCA biopharma. How were ARCA biopharma's earnings last quarter? ARCA biopharma, Inc. (NASDAQ:ABIO) released its quarterly earnings data on Monday, May, 2nd. The biopharmaceutical company reported ($0.23) EPS for the quarter. View ARCA biopharma's earnings history. Who are ARCA biopharma's key executives? ARCA biopharma's management team includes the following people: Dr. Michael R. Bristow M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 77, Pay $363.56k)Mr. Thomas A. Keuer, Chief Operating Officer (Age 63, Pay $360.58k)Mr. Christopher D. Ozeroff, Sr. VP, Gen. Counsel & Sec. (Age 63, Pay $318.86k)Mr. C. Jeffrey Dekker CPA, Chief Financial Officer (Age 57)Dr. Debra Marshall FACC, M.D., Chief Medical Officer What is Michael R. Bristow's approval rating as ARCA biopharma's CEO? 1 employees have rated ARCA biopharma CEO Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among ARCA biopharma's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of ARCA biopharma's key competitors? Some companies that are related to ARCA biopharma include VolitionRx (VNRX), VolitionRx (VNRX), OncoCyte (OCX), MyMD Pharmaceuticals (MYMD), Aspira Women's Health (AWH), Lucira Health (LHDX), ImmuCell (ICCC), Achieve Life Sciences (ACHV), Biomerica (BMRA), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Quotient (QTNT), Navidea Biopharmaceuticals (NAVB), Navidea Biopharmaceuticals (NAVB) and StageZero Life Sciences (SZLSF). View all of ABIO's competitors. What other stocks do shareholders of ARCA biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP). What is ARCA biopharma's stock symbol? ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO." How do I buy shares of ARCA biopharma? Shares of ABIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ARCA biopharma's stock price today? One share of ABIO stock can currently be purchased for approximately $2.48. How much money does ARCA biopharma make? ARCA biopharma (NASDAQ:ABIO) has a market capitalization of $35.74 million. The biopharmaceutical company earns $-19.32 million in net income (profit) each year or ($1.300010) on an earnings per share basis. How many employees does ARCA biopharma have? ARCA biopharma employs 17 workers across the globe. How can I contact ARCA biopharma? ARCA biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The official website for ARCA biopharma is arcabio.com. The biopharmaceutical company can be reached via phone at (720) 940-2200, via email at derek.cole@arcabio.com, or via fax at 720-208-9261. This page (NASDAQ:ABIO) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
